Conditional survival of patients with metastatic renal-cell carcinoma

The Lancet Oncology

Volumn 13, Issue 11, 2012, Pages

  Sun, Maxine ^a   Trinh, Quoc Dien ^a   Karakiewicz, Pierre I ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; EVEROLIMUS; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CONDITIONAL SURVIVAL; DATA BASE; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY METASTASIS; LETTER; LIFE EXPECTANCY; PATIENT CARE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; REIMBURSEMENT; SURVIVAL; SURVIVAL TIME;

CARCINOMA, RENAL CELL; HUMANS; INDOLES; NEOPLASM METASTASIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; PYRROLES; SIROLIMUS; SURVIVAL ANALYSIS;

EID: 84868097200     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70391-1     Document Type: Letter

References (5)

1. Skuladottir H, Olsen JH Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. J Clin Oncol 2003, 21:3035-3040.
2. Harshman LC, Xie W, Bjarnason GA, et al. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol 2012, 13:927-935.
3. Rini B, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
4. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116:4256-4265.
5. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.